Biblio Discovery — Demo Discovery Service

5 results for "Eric Hatterer"

Showing 1–5 · 0.23 seconds · RSS

  1. Journal Article Full text

    Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions.

    Eric Hatterer; Monique Touret; Marie-Françoise Belin et al.

    PLoS ONE, Vol. 3 No. 10 · 2008 · English · DOAJ Scopus

    BACKGROUND: In many neuroinflammatory diseases, dendritic cells (DCs) accumulate in several compartments of the central nervous system (CNS), including the cerebrospinal fluid (CSF). Myeloid DCs invading the inflamed CNS are thus thought to play a major role in the initiation and perpetuation of…

    Also available at: PLOS

  2. Journal Article

    Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies

    Camilla Jandus; Walter Ferlin; Sébastien Calloud et al.

    Journal for ImmunoTherapy of Cancer, Vol. 13 No. 3 · 2025 · English · DOAJ Scopus

    Background Owing to their roles in promoting T cell and natural killer (NK) cell activation and proliferation, interleukins-2 (IL-2) and interleukins-15 (IL-15) have been pursued as promising pathways to target in cancer immunotherapy. Nonetheless, their wider therapeutic application has been…

  3. Journal Article

    Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors

    Eric Hatterer; Xavier Chauchet; Françoise Richard et al.

    mAbs, Vol. 12 No. 1 · 2020 · English · DOAJ Scopus

    Mesothelin (MSLN) is a cell surface glycoprotein overexpressed in several solid malignancies, including gastric, lung, mesothelioma, pancreatic and ovarian cancers. While several MSLN-targeting therapeutic approaches are in development, only limited efficacy has been achieved in patients. A…

  4. Journal Article

    A third-generation, high-affinity biparatopic anti-tau antibody inhibits intracellular tau aggregation seeded by Alzheimer’s brain extracts

    Eric Hatterer; Lucile Broyer; Sara Pecoraro et al.

    Alzheimer’s Research & Therapy, Vol. 18 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background Tau immunotherapy has recently shown clinical promise but required high dosing. We developed NIDB-3101, a novel third-generation, high-affinity anti-tau biparatopic antibody designed for superior tau binding, aggregation inhibition, and extended half-life. Methods NIDB-3101…